Sorrento Therapeutics, Inc.
(NASDAQ : SRNE)

( )
SRNE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 0.80%61.580.0%$914.89m
NVAXNovavax, Inc. -5.99%98.30102.0%$790.47m
AMGNAmgen, Inc. -0.62%251.591.3%$725.25m
REGNRegeneron Pharmaceuticals, Inc. -0.08%640.342.5%$677.64m
GILDGilead Sciences, Inc. -1.06%75.611.0%$627.17m
BIIBBiogen, Inc. 4.41%280.191.6%$622.60m
VRTXVertex Pharmaceuticals, Inc. -1.05%295.921.9%$509.00m
ILMNIllumina, Inc. -0.61%369.873.5%$300.06m
ALXNAlexion Pharmaceuticals, Inc. -3.97%108.002.0%$219.47m
BMRNBioMarin Pharmaceutical, Inc. 0.59%128.734.3%$214.30m
SGENSeattle Genetics, Inc. -0.35%175.536.1%$200.21m
SRNESorrento Therapeutics, Inc. -1.22%7.291.8%$180.15m
IMMUImmunomedics, Inc. 0.95%41.5511.0%$179.47m
SRPTSarepta Therapeutics, Inc. 3.82%170.1513.9%$164.96m
ALNYAlnylam Pharmaceuticals, Inc. 0.26%160.428.5%$164.06m

Company Profile

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.